BioStock: Immunicum to present data for potential AML treatment

Acute myeloid leukaemia has one of the highest rates of recurrence after initial remission, and treatment options are limited. Immuno-oncology company Immunicum is addressing the issue by developing a cancer relapse vaccine, DCP-001. The company will present positive preclinical data at the CIMT meeting suggesting that DCP-001 works in synergy with conventional acute myeloid leukemia treatments to amplify the therapeutic effects. In parallel, the company is also on schedule to present novel clinical data on DCP-001 as a monotherapy later this quarter.

Read the article at biostock.se:

https://www.biostock.se/en/2022/05/immunicum-to-present-data-for-potential-aml-treatment/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se/en/